End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
118.4 CNY | +1.07% | +10.14% | -5.94% |
04-22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
04-22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.94% | 2.57B | - | ||
+3.45% | 30.13B | B- | ||
+7.00% | 22.12B | B | ||
+10.44% | 11.87B | B- | ||
+15.09% | 5.27B | C- | ||
+16.44% | 4.38B | B+ | ||
-15.24% | 3.53B | C | ||
+4.98% | 3.13B | C+ | ||
+28.84% | 2.91B | C+ | ||
-4.21% | 2.2B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688639 Stock
- Ratings Anhui Huaheng Biotechnology Co., Ltd.